• Methotrexate, EvoPure<sup>&reg;</sup>

click on thumbnail to zoom
SKU: M091

Quantity:
 
Price: make selection(s)
Description

Methotrexate is a selective agent for DHFR transfected cells and an anticancer compound that inhibits the metabolism of folic acid. Recently it is much more commonly perscribed as an immunosuppresant drug to assist with joint pain in rheumatoid arthritis and psoriasis. Methotrexate, EvoPure® is manufactured in Ghent, Belgium, and has been fully characterized by FTIR, HNMR, HPLC, and mass spectrometry. Methotrexate, EvoPure® is suitable for use as an ancillary material in upstream biomanufacturing applications and processes.

CHO cells and other mammalian cells used in biopharmacutical manufacturing applications are delicate organisms that may respond poorly to lower quality research or USP grade methotrexate. TOKU-E understands each manufacturing process is different and requires strict and unique quality specifications for maximum yield. The specifications for methotrexate, EvoPure® can be changed or modified to meet your unique needs and specifications.

For this reason, please contact us for pricing and more information.

    CAS Number

    59-05-2

    Molecular Formula

    C20H22N8O5

    Molecular Weight

    454.44

    Mechanism of Action

    Methotrexate acts as an allosteric inhibitor of dihydrofolate reductase (DHFR), an enzyme involved in the folic acid metabolic pathway. Folic acid is essential in cells because it is required for thymidine and purine synthesis. Methotrexate therefore acts as a nucleic acid synthesis inhibitor.

Applications

    Cancer Applications

    Methotrexate acts as a chemotherapeutic agent by inhibiting nucleic acid synthesis in cancer cells.

    Eukaryotic Cell Culture Applications

    Methotrexate is commonly used in the dihydrofolate reductase (DHFR) selection system as a selection antibiotic to select for dihydrofolate reductase (DHFR) deficient CHO cells (Chinese hamster ovary) that have been transfected with DHFR genes. Methotrexate inhibits the activity of DHFR; however, cells that overproduce DHFR can tolerate higher concentrations of methotrexate. In most cases, overproducing DHFR cells produce more recombinant protein than lower DHFR producing cells.

Specifications

    Form

    Powder

References

    References

    Fairbanks, L. D., and Et Al. "Methotrexate Inhibits the First Committed Step of Purine Biosynthesis in Mitogen-stimulated Human T-lymphocytes: A Metabolic Basis for Efficacy in Rheumatoid Arthritis?" Biochemistry Journal 342.1 (1999): 143-52. www.ncbi.gov. Web. 6 Sept. 2012.

    Kingston, RE. "Amplification Using CHO Cell Expression Vectors." Current Protocols in Molecular Biology. U.S. National Library of Medicine, Nov. 2002. Web. 23 Dec. 2016.

Other Items In This Category